EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing multi-mechanism drugs that target disease cells directly and the blood vessels that nourish them. We are focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes.
EntreMed’s goal is to develop and commercialize therapeutics based on the Company’s scientific expertise in angiogenesis, cell cycle regulation, cell signaling, and inflammation — processes vital to the progression of cancer and other diseases. The Company’s three clinical product candidates for oncology are based on these mechanisms. The Company’s expertise has also led to the identification of new molecules, including new chemical entities that cause apoptosis and cell cycle arrest, as well as new chemical entities associated with Aurora/angiogenesis inhibition and histone deacetylase (HDAC) inhibition, important targets in the treatment of oncology.
EntreMed is developing orally-administered, small molecule compounds that have broad therapeutic and commercial potential in oncology and inflammatory diseases. In order to further advance its commercial objectives, EntreMed may seek strategic alliances, licensing relationships and co-development partnerships with other companies to develop compounds for both oncology and non-oncology therapeutic areas.
Our Product Candidates
MKC-1, a novel, orally-active cell cycle inhibitor, is currently in multiple Phase 1 and Phase 2 clinical trials, including metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), hematological cancers, ovarian and endometrial cancer, and pancreatic cancer.
ENMD-1198, a potent, orally-active, antimitotic agent, is currently in a Phase 1 dose-escalation clinical trial in patients with refractory solid tumors. Completion of the study is expected around mid-2008 with a further trial expected in the second half of 2008.
ENMD-2076 is an orally-active selective kinase inhibitor with a unique kinase profile, including antiproliferative activity and inhibition of angiogenesis. EntreMed’s IND has been accepted by the FDA and a Phase 1 study in solid tumors is expected to enroll patients in early 2Q08.
Panzem® (2-methoxyestradiol, 2ME2) is moving forward in rheumatoid arthritis based on the knowledge gained from the oncology development effort and favorable preclinical research results showing that 2ME2 has disease modifying or “DMARD” activity. The FDA has accepted EntreMed’s IND for 2ME2 in RA, which included an extensive human safety dossier in 300 patients from prior oncology studies. Panzem® for RA represents a safe, orally administered, small molecule alternative to current biologicals and a potential “first-in-class” cross-over opportunity from oncology. The Company plans to initiate a normal volunteer clinical trial in 2008 and seek a development partner to manage larger multi-arm Phase 2 and Phase 3 studies.
James S. Burns, President & CEO
Dane Saglio, Chief Financial Officer
Cynthia Wong Hu, Vice President, General Counsel and Corporate Secretary
Carolyn F. Sidor, M.D., MBA, Vice President and Chief Medical Officer
Kenneth W. Bair, Ph.D., Senior Vice President, Research and Development
Associate Director, Corporate Communications & Investor Relations